



25th January, 2024

To, The Manager - Listing Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: 524212	To, The Manager – Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Plot No. C/1, G - Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051. Scrip Symbol: WANBURY
--	--

Sub: Press release on Q3 & 9M FY24 Financial Results

Dear Sir/Madam,

Please find attached herewith copy of press release on Q3 & 9M FY24 Financial Results.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd

Jitendra J. Gandhi
Company Secretary

Encl.: a/a.



Wanbury Ltd. net profit up 40% at Rs. 10.3 cr in Q3FY24 versus Rs 7.4 cr in Q2FY24

25th January, 2024, MUMBAI: Wanbury Ltd, one of India's fast growing pharmaceutical company having a presence in API global market and domestic branded Formulation, announced its financial results for the third quarter and nine months ended December 31, 2023.

Consolidated Q3 & 9M FY24 Financial Highlights

(Rs in Crore)

Particulars	Q3 FY24	Q2 FY24	% QoQ	Q3 FY23	% YoY	9M FY24	9M FY23	% YoY
Revenue from Operations	146.2	145.2	1%	126.0	16%	438.3	369.6	19%
EBITDA	21.8	18.1	21%	6.7	225%	53.9	12.0	350%
EBITDA Margin (%)	15%	12%	300 bps	5%	1000 bps	12%	3%	900 bps
PAT	10.3	7.4	40%	-3.3	-	22.3	-11.4	-
PAT Margin (%)	7%	5%	200 bps	-	-	5%	-	-

Commenting on the performance, **Mr Mohan Rayana, Director, Wanbury Ltd.** said, "The results declared for Q3 & 9MFY24 marks a significant milestone in the history of the company registering its highest ever quarterly EBITDA of Rs. 22 crore and nine month EBITDA of Rs. 54 crore which is 225% and 350% higher compared to the same periods last year. This is attributed to increase in sales volume, besides yield improvement and process engineering initiatives on existing products has led to improved operating margins. As a long-term strategy, we plan to expand our API product portfolio and focus on different therapeutic areas which will propel sustainable growth.

Over the years our endeavour has been to reduce debt and as a result our debt currently stands at Rs. 117 crore."



About Wanbury Limited:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The Company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Taramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The Company's clients include some of the leading global generic players.

In formulations, the Company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi
Company Secretary,
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills Compound, City Hall,
Pandurang Budhkar Marg, Lower Parel West,
Mumbai – 400021
Tel: +91 9619059339 / +91 7021852071
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.